A new paradigm for sepsis screening Introducing PliNOSa K-1600*, a novel in vitro diagnostic immunoassay test for the early identification of sepsis. PliNOSa measures inducible nitric oxide synthase (iNOS) on microvesicles, a new paradigm of disease pathology and can help physicians make more informed choices. Until now, sepsis has always been an intractable disease that has often baffled medical researchers. Biomarkers such as procalcitonin (PCT), IL-6, lactate, and CRP have lacked the necessary specificity and sensitivity. These assays often fail to help physicians and clinicians to distinguish at-risk patient populations from those not at risk. PliNOSa helps physicians assess a patient's risk of developing sepsis as much as 48 hours before symptoms are recognizable. Research and Diagnostic Antibodies has delivered high quality research antibodies to the life sciences and research markets since 1984. The company has 19 issued patents covering the PliNOSa test and detecting the onset of sepsis and is also developing aSeptiMab, a candidate monoclonal antibody therapeutic for the treatment of sepsis. R&D Antibodies gratefully acknowledges the contributions of the US Department of Health and Human Services, National Institutes of Health for grant funding received to enable the company to complete three peer-reviewed clinical studies for PliNOSa. * In the EU, this device cannot be marketed or put into service until it complies with the requirements of the IVD Directive (98/79/EC) and obtains a CE mark (anticipated October 2015).